Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Belichenko

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 8, 2009
The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndromeNadia P Belichenko, Pavel V Belichenko, Alexander M Kleschevnikov, et al.
Gene Therapy|February 17, 2006
Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I miceG Watson, J Bastacky, P Belichenko, et al.
Plos One|August 26, 2014
A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progressionDanielle A Simmons, Juliet K Knowles, Nadia P Belichenko, et al.
The Journal of Comparative Neurology|March 20, 2009
Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networksPavel V Belichenko, Elena E Wright, Nadia P Belichenko, et al.
Molecular Genetics and Metabolism|October 7, 2004
Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS IE Kakkis, M McEntee, C Vogler, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 29, 2013
A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's diseaseDanielle A Simmons, Nadia P Belichenko, Tao Yang, et al.
Human Molecular Genetics|June 4, 2018
TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31Danielle A Simmons, Michelle L James, Nadia P Belichenko, et al.
Acta Neuropathologica Communications|September 26, 2018
Alzheimer's associated amyloid and tau deposition co-localizes with a homeostatic myelin repair pathway in two mouse models of post-stroke mixed dementiaThuy-Vi V Nguyen, Megan Hayes, Jacob C Zbesko, et al.
Human Molecular Genetics|February 8, 2017
A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD miceDanielle A Simmons, Nadia P Belichenko, Ellen C Ford, et al.
Journal of Alzheimer'S Disease : JAD|June 6, 2014
Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic miceThuy-Vi V Nguyen, Lin Shen, Lilith Vander Griend, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 8, 2009
The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndromeNadia P Belichenko, Pavel V Belichenko, Alexander M Kleschevnikov, et al.
Gene Therapy|February 17, 2006
Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I miceG Watson, J Bastacky, P Belichenko, et al.
Plos One|August 26, 2014
A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progressionDanielle A Simmons, Juliet K Knowles, Nadia P Belichenko, et al.
The Journal of Comparative Neurology|March 20, 2009
Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networksPavel V Belichenko, Elena E Wright, Nadia P Belichenko, et al.
Molecular Genetics and Metabolism|October 7, 2004
Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS IE Kakkis, M McEntee, C Vogler, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 29, 2013
A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's diseaseDanielle A Simmons, Nadia P Belichenko, Tao Yang, et al.
Human Molecular Genetics|June 4, 2018
TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31Danielle A Simmons, Michelle L James, Nadia P Belichenko, et al.
Acta Neuropathologica Communications|September 26, 2018
Alzheimer's associated amyloid and tau deposition co-localizes with a homeostatic myelin repair pathway in two mouse models of post-stroke mixed dementiaThuy-Vi V Nguyen, Megan Hayes, Jacob C Zbesko, et al.
Human Molecular Genetics|February 8, 2017
A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD miceDanielle A Simmons, Nadia P Belichenko, Ellen C Ford, et al.
Journal of Alzheimer'S Disease : JAD|June 6, 2014
Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic miceThuy-Vi V Nguyen, Lin Shen, Lilith Vander Griend, et al.
Pageof 3